Although the trial revealed that the low-grade toxicities were manageable and the regimen was well-tolerated, the results indicated that this combination of low-dose GM-CSF, IFN-α, and IL-2 did not improve disease-free survival (DFS), compared to historical controls in patients with surgically resected high-risk RCC [40]. Here, IL2 is linked to renal cell carcinoma.